Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136196 | 0.87 | CNR2 (0.44) | CNR2HSD11B1ABL1CFTRNPC1 | |
| SCHEMBL25136198 | 0.87 | CNR2 (0.44) | CNR2HSD11B1ABL1CFTRNPC1 | |
| SCHEMBL25136256 | 0.79 | KMO (0.37) | CNR2SMYD3ABL1PLAT | |
| SCHEMBL25135906 | 0.68 | AXL (0.38) | CNR2ABL1AXL | |
| SCHEMBL25136066 | 0.68 | CNR2 (0.40) | CNR2ABL1NPC1 | |
| SCHEMBL25136136 | 0.68 | CNR2 (0.40) | CNR2ABL1NPC1 | |
| SCHEMBL30039263 | 0.66 | CD38 (0.44) | MAPT | |
| SCHEMBL25136085 | 0.65 | KMO (0.37) | CNR2ABL1 | |
| SCHEMBL25136129 | 0.65 | KMO (0.37) | CNR2ABL1NPC1RAB9A | |
| SCHEMBL25136144 | 0.65 | KMO (0.37) | CNR2ABL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | CNR2 547/4885SMYD3 2117/4885HSD11B1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.